EP3388140A1 - Circuit de circulation extra-corporelle - Google Patents

Circuit de circulation extra-corporelle Download PDF

Info

Publication number: EP3388140A1
Authority: EP; European Patent Office
Prior art keywords: blood circuit; extracorporeal blood; membranes; extracorporeal; cardiopulmonary bypass
Prior art date: 2017-04-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP17165657.2A

Other languages

German (de)

English (en)

Inventor

Kai Harenski

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Gambro Lundia AB

Original Assignee

Gambro Lundia AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-04-10

Filing date

2017-04-10

Publication date

2018-10-17

2017-04-10 Application filed by Gambro Lundia AB filed Critical Gambro Lundia AB

2017-04-10 Priority to EP17165657.2A priority Critical patent/EP3388140A1/fr

2018-04-10 Priority to JP2020504439A priority patent/JP7217737B2/ja

2018-04-10 Priority to PCT/EP2018/059098 priority patent/WO2018189142A1/fr

2018-04-10 Priority to CN201880020603.4A priority patent/CN110461449A/zh

2018-04-10 Priority to EP18721695.7A priority patent/EP3609608A1/fr

2018-04-10 Priority to US16/603,695 priority patent/US20200055004A1/en

2018-10-17 Publication of EP3388140A1 publication Critical patent/EP3388140A1/fr

Status Withdrawn legal-status Critical Current

Links

210000004369 blood Anatomy 0.000 title claims abstract description 40
239000008280 blood Substances 0.000 title claims abstract description 40
230000002612 cardiopulmonary effect Effects 0.000 claims abstract description 16
239000012528 membrane Substances 0.000 claims description 44
238000001914 filtration Methods 0.000 claims description 17
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 14
229960002897 heparin Drugs 0.000 claims description 14
229920000669 heparin Polymers 0.000 claims description 14
229920002873 Polyethylenimine Polymers 0.000 claims description 13
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 11
229920001577 copolymer Polymers 0.000 claims description 10
SZHIIIPPJJXYRY-UHFFFAOYSA-M sodium;2-methylprop-2-ene-1-sulfonate Chemical compound [Na+].CC(=C)CS([O-])(=O)=O SZHIIIPPJJXYRY-UHFFFAOYSA-M 0.000 claims description 9
238000002618 extracorporeal membrane oxygenation Methods 0.000 claims description 6
239000012510 hollow fiber Substances 0.000 claims description 6
239000002158 endotoxin Substances 0.000 description 15
230000002757 inflammatory effect Effects 0.000 description 10
102000004127 Cytokines Human genes 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
239000007789 gas Substances 0.000 description 9
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
125000000129 anionic group Chemical group 0.000 description 8
102000004889 Interleukin-6 Human genes 0.000 description 7
108090001005 Interleukin-6 Proteins 0.000 description 7
230000004087 circulation Effects 0.000 description 7
102000003814 Interleukin-10 Human genes 0.000 description 6
108090000174 Interleukin-10 Proteins 0.000 description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
229920006008 lipopolysaccharide Polymers 0.000 description 6
229920000642 polymer Polymers 0.000 description 5
238000000108 ultra-filtration Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
102100040247 Tumor necrosis factor Human genes 0.000 description 4
229910002092 carbon dioxide Inorganic materials 0.000 description 4
239000001569 carbon dioxide Substances 0.000 description 4
229920006317 cationic polymer Polymers 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
-1 polypropylene Polymers 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
239000003146 anticoagulant agent Substances 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
238000000034 method Methods 0.000 description 3
230000008439 repair process Effects 0.000 description 3
238000002965 ELISA Methods 0.000 description 2
238000012404 In vitro experiment Methods 0.000 description 2
241001065350 Lundia Species 0.000 description 2
239000002033 PVDF binder Substances 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
239000000835 fiber Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229920002239 polyacrylonitrile Polymers 0.000 description 2
229920001343 polytetrafluoroethylene Polymers 0.000 description 2
239000004810 polytetrafluoroethylene Substances 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000009564 veno-arterial ECMO Methods 0.000 description 2
238000009565 veno-venous ECMO Methods 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
WSSSPWUEQFSQQG-UHFFFAOYSA-N 4-methyl-1-pentene Chemical compound CC(C)CC=C WSSSPWUEQFSQQG-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
208000002330 Congenital Heart Defects Diseases 0.000 description 1
102100037907 High mobility group protein B1 Human genes 0.000 description 1
101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 description 1
229920001202 Inulin Polymers 0.000 description 1
BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
241000239218 Limulus Species 0.000 description 1
102000036675 Myoglobin Human genes 0.000 description 1
108010062374 Myoglobin Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000000274 adsorptive effect Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
208000028831 congenital heart disease Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
108010072542 endotoxin binding proteins Proteins 0.000 description 1
230000006870 function Effects 0.000 description 1
208000025339 heart septal defect Diseases 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
229940076144 interleukin-10 Drugs 0.000 description 1
229940100601 interleukin-6 Drugs 0.000 description 1
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
229940029339 inulin Drugs 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000001706 oxygenating effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
238000009832 plasma treatment Methods 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005597 polymer membrane Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007873 sieving Methods 0.000 description 1
238000012421 spiking Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
238000004381 surface treatment Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000008718 systemic inflammatory response Effects 0.000 description 1
238000013151 thrombectomy Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/14—Dynamic membranes
- B01D69/141—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes
- B01D69/147—Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes containing embedded adsorbents
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1621—Constructional aspects thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1698—Blood oxygenators with or without heat-exchangers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3666—Cardiac or cardiopulmonary bypass, e.g. heart-lung machines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
- A61M1/3673—Anticoagulant coating, e.g. Heparin coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/40—Polymers of unsaturated acids or derivatives thereof, e.g. salts, amides, imides, nitriles, anhydrides, esters
- B01D71/42—Polymers of nitriles, e.g. polyacrylonitrile
- B01D71/421—Polyacrylonitrile
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/76—Macromolecular material not specifically provided for in a single one of groups B01D71/08 - B01D71/74
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/76—Macromolecular material not specifically provided for in a single one of groups B01D71/08 - B01D71/74
- B01D71/82—Macromolecular material not specifically provided for in a single one of groups B01D71/08 - B01D71/74 characterised by the presence of specified groups, e.g. introduced by chemical after-treatment
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/12—Adsorbents being present on the surface of the membranes or in the pores
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/16—Membrane materials having positively charged functional groups

Definitions

the diffusion- and/or filtration device removes excessive water from the patient by ultrafiltration and also adsorbs inflammatory mediators from the blood of the patient.
suitable diffusion- and/or filtration devices include commercial capillary dialyzers available from Gambro Lundia AB under the trade names oXiris ® and Evodial ® .
the dialyzer comprises hollow fiber membranes comprising a copolymer of acrylonitrile and sodium methallyl sulfonate.
the surface of the fibers comprises 30 mg/m 2 of high MW polyethyleneimine (PEI) and is grafted with 4,500 ⁇ 1,500 UI/m 2 of heparin.
PEI polyethyleneimine
the fibers have an inner diameter of 240 ⁇ m and a wall strength of 40 ⁇ m.
HMGB-1 High-mobility group box 1
TNF-a Tumor necrosis factor alpha
LPS Lipopolysaccharide
the circulation conditions are representative of standard CRRT practices.

Landscapes

Health & Medical Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Chemical & Material Sciences (AREA)
Vascular Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Dispersion Chemistry (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Surgery (AREA)
External Artificial Organs (AREA)
Separation Using Semi-Permeable Membranes (AREA)

EP17165657.2A 2017-04-10 2017-04-10 Circuit de circulation extra-corporelle Withdrawn EP3388140A1 (fr)

Priority Applications (6)

Application Number	Priority Date	Filing Date	Title
EP17165657.2A EP3388140A1 (fr)	2017-04-10	2017-04-10	Circuit de circulation extra-corporelle
JP2020504439A JP7217737B2 (ja)	2017-04-10	2018-04-10	体外血液回路
PCT/EP2018/059098 WO2018189142A1 (fr)	2017-04-10	2018-04-10	Circuit sanguin extracorporel
CN201880020603.4A CN110461449A (zh)	2017-04-10	2018-04-10	体外血液回路
EP18721695.7A EP3609608A1 (fr)	2017-04-10	2018-04-10	Circuit sanguin extracorporel
US16/603,695 US20200055004A1 (en)	2017-04-10	2018-04-10	Extracorporeal blood circuit

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP17165657.2A EP3388140A1 (fr)	2017-04-10	2017-04-10	Circuit de circulation extra-corporelle

Publications (1)

Publication Number	Publication Date
EP3388140A1 true EP3388140A1 (fr)	2018-10-17

Family

ID=58530425

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP17165657.2A Withdrawn EP3388140A1 (fr)	2017-04-10	2017-04-10	Circuit de circulation extra-corporelle
EP18721695.7A Pending EP3609608A1 (fr)	2017-04-10	2018-04-10	Circuit sanguin extracorporel

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP18721695.7A Pending EP3609608A1 (fr)	2017-04-10	2018-04-10	Circuit sanguin extracorporel

Country Status (5)

Country	Link
US (1)	US20200055004A1 (fr)
EP (2)	EP3388140A1 (fr)
JP (1)	JP7217737B2 (fr)
CN (1)	CN110461449A (fr)
WO (1)	WO2018189142A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN111182929B (zh)	2017-09-17	2023-08-15	S·P·凯勒	用于体外去除二氧化碳的系统、装置和方法
CN114340771A (zh) *	2019-08-26	2022-04-12	住友化学株式会社	酸性气体分离膜、酸性气体分离装置、酸性气体分离膜的制造方法以及酸性气体分离方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999047190A1 (fr) *	1998-03-16	1999-09-23	Medtronic, Inc.	Systeme et constituants hemostatiques pour circuit extracorporel
US20030021826A1 (en)	2000-01-27	2003-01-30	Thierry Crost	Non-thrombogenic semipermeable membrane and method for making same
WO2007148147A1 (fr)	2006-06-22	2007-12-27	Gambro Lundia Ab	Utilisation d'une suspension colloïdale d'un polymère cationique pour traiter un support à usage médical

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5277176A (en) *	1992-06-29	1994-01-11	Habashi Nader M	Extracorporeal lung assistance apparatus and process
US7473239B2 (en) *	2003-08-25	2009-01-06	The University Of Texas System	Single expandable double lumen cannula assembly for veno-venous ECMO
CN2738809Y (zh) *	2004-10-15	2005-11-09	复旦大学附属中山医院	血液净化和体外膜氧合一体化装置
CN101842111A (zh) *	2007-08-31	2010-09-22	密执安州立大学董事会	选择性细胞隔离装置及其相关方法
US8518259B2 (en) *	2011-01-27	2013-08-27	Medtronic, Inc.	De-airing oxygenator for treating blood in an extracorporeal blood circuit
US8685319B2 (en) *	2011-04-29	2014-04-01	Medtronic, Inc.	Combination oxygenator and arterial filter device with a fiber bundle of continuously wound hollow fibers for treating blood in an extracorporeal blood circuit
US9511087B2 (en) *	2012-08-03	2016-12-06	Revo Biologics, Inc.	Use of antithrombin in extracorporeal membrane oxygenation
CN106255520B (zh) *	2014-04-24	2022-08-12	艾克塞拉医疗公司	使用高流速从血液除去细菌的方法

2017
- 2017-04-10 EP EP17165657.2A patent/EP3388140A1/fr not_active Withdrawn
2018
- 2018-04-10 WO PCT/EP2018/059098 patent/WO2018189142A1/fr unknown
- 2018-04-10 US US16/603,695 patent/US20200055004A1/en not_active Abandoned
- 2018-04-10 CN CN201880020603.4A patent/CN110461449A/zh active Pending
- 2018-04-10 JP JP2020504439A patent/JP7217737B2/ja active Active
- 2018-04-10 EP EP18721695.7A patent/EP3609608A1/fr active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999047190A1 (fr) *	1998-03-16	1999-09-23	Medtronic, Inc.	Systeme et constituants hemostatiques pour circuit extracorporel
US20030021826A1 (en)	2000-01-27	2003-01-30	Thierry Crost	Non-thrombogenic semipermeable membrane and method for making same
WO2007148147A1 (fr)	2006-06-22	2007-12-27	Gambro Lundia Ab	Utilisation d'une suspension colloïdale d'un polymère cationique pour traiter un support à usage médical

Also Published As

Publication number	Publication date
JP2020516424A (ja)	2020-06-11
CN110461449A (zh)	2019-11-15
EP3609608A1 (fr)	2020-02-19
US20200055004A1 (en)	2020-02-20
JP7217737B2 (ja)	2023-02-03
WO2018189142A1 (fr)	2018-10-18

Publication	Publication Date	Title
US6605218B2 (en)	2003-08-12	Dialyzers for blood treatment and processes for production thereof
US11478757B2 (en)	2022-10-25	High cut-off hemodialysis membrane for use in liver dialysis
JP5199252B2 (ja)	2013-05-15	医学的な使用のための支持体を処理するための陽イオン性ポリマーのコロイド懸濁液の使用
US8771516B2 (en)	2014-07-08	Membranes having improved performance
US5418061A (en)	1995-05-23	Microporous polysulfone supports suitable for removal of low density lipoprotein-cholesterol
AU2013349977A1 (en)	2015-06-11	Liver support system
EP2042230B1 (fr)	2010-12-22	Membranes hydrophiles dotées d'un agent tensioactif non ionique
JP4061798B2 (ja)	2008-03-19	血液処理用半透膜およびそれを用いた血液処理用透析器
JPH0623043A (ja)	1994-02-01	全血からの低密度リポ蛋白−コレステロールの高性能除去
Su et al.	2011	Polyethersulfone hollow fiber membranes for hemodialysis
CN105709613A (zh)	2016-06-29	一种有效去除中等生物分子的纳米纤维复合膜及其制备方法和应用
JP7217737B2 (ja)	2023-02-03	体外血液回路
JPH0852209A (ja)	1996-02-27	血液処理のための多機能装置
EP0570232A2 (fr)	1993-11-18	Supports de microporeux de polysulfone utilisable pour enlever le cholestérol lipoprotéinique de faible densité
JP4893099B2 (ja)	2012-03-07	人工腎臓
JP2003290638A (ja)	2003-10-14	ポリスルホン系半透膜およびそれを用いた人工腎臓
JP2010136803A (ja)	2010-06-24	血液からウイルス及びサイトカインを除去するシステム
WO2024150779A1 (fr)	2024-07-18	Membrane semi-perméable et module à membrane semi-perméable
JP4003982B2 (ja)	2007-11-07	ポリスルホン系選択透過性分離膜
Patil et al.	2022	Comprehensive Study of Cellulosic and Synthetic Membranes for Dialyzer
JP4830181B2 (ja)	2011-12-07	過酸化脂質吸着用中空糸膜およびそれを用いたモジュール
JP2000210544A (ja)	2000-08-02	半透膜の製造方法
JP2002102692A (ja)	2002-04-09	過酸化脂質吸着材の製造方法
JPH0970526A (ja)	1997-03-18	選択透過性分離膜

Legal Events

Date	Code	Title	Description
2018-09-14	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-10-17	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-10-17	AX	Request for extension of the european patent	Extension state: BA ME
2019-08-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2019-10-02	18D	Application deemed to be withdrawn	Effective date: 20190418